Mon Dec 19, 2022 – 3:17 pm EST
(LifeSiteNews) – A recent study by researchers with the U.S. Food & Drug Administration (FDA) found that Pfizer’s mRNA-based COVID-19 vaccine “met the threshold for a statistical signal” of blood clotting in the lungs of recipients aged 65 and older, as well as weaker thresholds for other complications, but the agency still maintains the benefits outweigh the risks.
The study, published December 1 in Vaccine, reviewed data pertaining to fourteen “outcomes of interest” after vaccination from more than 30 million elderly Americans spanning December 11, 2020 through January 15, 2022, and compared the rates to the pre-vaccine historical rates for the ailments.
It found that outcomes of pulmonary embolism, acute myocardial infarction, disseminated intravascular coagulation, and immune thrombocytopenia initially “met the threshold for a statistical signal,” and that following additional evaluation pulmonary embolism “still met the statistical threshold for a signal.”
While acknowledging that the findings warrant “more robust epidemiologic studies with adjustment for confounding, including age and nursing home residency” (which they claimed are underway), the authors took pains to downplay their significance.
“The statistical signals of four serious outcomes are not necessarily causal and may be
The remainder of this article is available in its entirety at LifeSite News
The views expressed in this news alert by the author do not directly represent that of The Official Street Preachers or its editors
